OSE Immunotherapeutics Announces Positive Recommendation from Independent Data Monitoring Committee (IDMC) to Continue Pivotal Phase 3 ARTEMIA Trial Evaluating Tedopi® in Non-Small Cell Lung Cancer
(State on share capital and voting rights in FR)
You confirm that you have read our privacy policy. You can unsubscribe at any time by using the unsubscribe links.